Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion

Aim. To evaluate the effectiveness and safety of cavutilide in patients with a history of unsuccessful cardioversion to terminate current persistent and paroxysmal atrial fibrillation (AF) episode.Material and methods. The retrospective study included 55 patients (mean age 60±8 years; male/female ra...

Full description

Saved in:
Bibliographic Details
Main Authors: Kh. M. Dzaurova, N. Yu. Mironov, Yu. A. Yuricheva, M. M. Belyaeva, S. F. Sokolov, N. A. Mironova, S. P. Golitsyn, O. Yu. Korennova, I. M. Zueva, E. A. Turusheva, D. S. Terekhov
Format: Article
Language:English
Published: Столичная издательская компания 2025-06-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/3152
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227491962519552
author Kh. M. Dzaurova
N. Yu. Mironov
Yu. A. Yuricheva
M. M. Belyaeva
S. F. Sokolov
N. A. Mironova
S. P. Golitsyn
O. Yu. Korennova
I. M. Zueva
E. A. Turusheva
D. S. Terekhov
author_facet Kh. M. Dzaurova
N. Yu. Mironov
Yu. A. Yuricheva
M. M. Belyaeva
S. F. Sokolov
N. A. Mironova
S. P. Golitsyn
O. Yu. Korennova
I. M. Zueva
E. A. Turusheva
D. S. Terekhov
author_sort Kh. M. Dzaurova
collection DOAJ
description Aim. To evaluate the effectiveness and safety of cavutilide in patients with a history of unsuccessful cardioversion to terminate current persistent and paroxysmal atrial fibrillation (AF) episode.Material and methods. The retrospective study included 55 patients (mean age 60±8 years; male/female ratio 37/18) with paroxysmal (n=15) and persistent (n=40), who had unsuccessfully attempted to terminate the current episode of arrhythmia using electrocardiography. All patients received сavutilide in the intensive care unit according to the following regimen: 5 μg/kg-5 μg/kg-10 μg/kg-10 μg/kg. After each bolus and before the next one, ECG parameters (rhythm, QT interval) and the patients’ general condition were assessed; the interval between administrations was 15 minutes. Administration was halted if sinus rhythm (SR) was restored, heart rate (HR) fell below 50 bpm, QTc exceeded 500 ms, or arrhythmogenic effects occurred. Patients were monitored telemetrically for 24 hours to assess efficacy and safety.Results. SR was restored in 47 (85.4%) out of 55 patients, with a median restoration time of 40 [15-240] minutes. Five patients (9%) achieved SR after the initial of 5 μg/kg dose. Sixteen additional patients responded to 10 μg/kg (cumulative efficacy: 38%). Nine further patients achieved SR at 20 μg/kg (cumulative efficacy: 54.5%). The remaining patients required the maximum 30 μg/kg dose. QTc prolongation >500 ms occurred in 12 (21.8%) patients, though none developed sustained ventricular arrhythmias. Transient HR reduction <50 bpm occurred in 4/55 patients (7.2%) during arrhythmia termination.Conclusion. Cavutilide demonstrates high effectiveness and safety in restoring heart rhythm in patients with prior unsuccessful electrical cardioversion attempts. These findings support considering pharmacological cardioversion with cavutilide in such cases.
format Article
id doaj-art-492f4f0f4a1c4ef0a988fa2f768fd71b
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2025-06-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-492f4f0f4a1c4ef0a988fa2f768fd71b2025-08-23T10:00:37ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532025-06-0121211912510.20996/1819-6446-2025-31522274Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversionKh. M. Dzaurova0N. Yu. Mironov1Yu. A. Yuricheva2M. M. Belyaeva3S. F. Sokolov4N. A. Mironova5S. P. Golitsyn6O. Yu. Korennova7I. M. Zueva8E. A. Turusheva9D. S. Terekhov10E. I. Chazov National Medical Research Center of CardiologyE. I. Chazov National Medical Research Center of CardiologyE. I. Chazov National Medical Research Center of CardiologyE. I. Chazov National Medical Research Center of CardiologyE. I. Chazov National Medical Research Center of CardiologyE. I. Chazov National Medical Research Center of CardiologyE. I. Chazov National Medical Research Center of CardiologyClinical Cardiology DispensaryClinical Cardiology DispensaryClinical Cardiology DispensaryRegional Clinical Cardiology DispensaryAim. To evaluate the effectiveness and safety of cavutilide in patients with a history of unsuccessful cardioversion to terminate current persistent and paroxysmal atrial fibrillation (AF) episode.Material and methods. The retrospective study included 55 patients (mean age 60±8 years; male/female ratio 37/18) with paroxysmal (n=15) and persistent (n=40), who had unsuccessfully attempted to terminate the current episode of arrhythmia using electrocardiography. All patients received сavutilide in the intensive care unit according to the following regimen: 5 μg/kg-5 μg/kg-10 μg/kg-10 μg/kg. After each bolus and before the next one, ECG parameters (rhythm, QT interval) and the patients’ general condition were assessed; the interval between administrations was 15 minutes. Administration was halted if sinus rhythm (SR) was restored, heart rate (HR) fell below 50 bpm, QTc exceeded 500 ms, or arrhythmogenic effects occurred. Patients were monitored telemetrically for 24 hours to assess efficacy and safety.Results. SR was restored in 47 (85.4%) out of 55 patients, with a median restoration time of 40 [15-240] minutes. Five patients (9%) achieved SR after the initial of 5 μg/kg dose. Sixteen additional patients responded to 10 μg/kg (cumulative efficacy: 38%). Nine further patients achieved SR at 20 μg/kg (cumulative efficacy: 54.5%). The remaining patients required the maximum 30 μg/kg dose. QTc prolongation >500 ms occurred in 12 (21.8%) patients, though none developed sustained ventricular arrhythmias. Transient HR reduction <50 bpm occurred in 4/55 patients (7.2%) during arrhythmia termination.Conclusion. Cavutilide demonstrates high effectiveness and safety in restoring heart rhythm in patients with prior unsuccessful electrical cardioversion attempts. These findings support considering pharmacological cardioversion with cavutilide in such cases.https://www.rpcardio.online/jour/article/view/3152сavutiliderefralonatrial fibrillationatrial flutterelectrical cardioversioncardioversionantiarrhythmic drugobesity
spellingShingle Kh. M. Dzaurova
N. Yu. Mironov
Yu. A. Yuricheva
M. M. Belyaeva
S. F. Sokolov
N. A. Mironova
S. P. Golitsyn
O. Yu. Korennova
I. M. Zueva
E. A. Turusheva
D. S. Terekhov
Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
Рациональная фармакотерапия в кардиологии
сavutilide
refralon
atrial fibrillation
atrial flutter
electrical cardioversion
cardioversion
antiarrhythmic drug
obesity
title Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
title_full Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
title_fullStr Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
title_full_unstemmed Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
title_short Effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
title_sort effectiveness of сavutilide in restoring sinus rhythm in patients with atrial fibrillation and flutter following prior unsuccessful electrical cardioversion
topic сavutilide
refralon
atrial fibrillation
atrial flutter
electrical cardioversion
cardioversion
antiarrhythmic drug
obesity
url https://www.rpcardio.online/jour/article/view/3152
work_keys_str_mv AT khmdzaurova effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT nyumironov effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT yuayuricheva effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT mmbelyaeva effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT sfsokolov effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT namironova effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT spgolitsyn effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT oyukorennova effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT imzueva effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT eaturusheva effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion
AT dsterekhov effectivenessofsavutilideinrestoringsinusrhythminpatientswithatrialfibrillationandflutterfollowingpriorunsuccessfulelectricalcardioversion